These entrepreneurial scientists founded startups in the past year to commercialize technologies they developed at the Wyss Institute
By Seth Kroll
(BOSTON) – Wyss Lumineers, members of our community that commit themselves to science and entrepreneurship, embody the Institute’s mission to transform healthcare and the environment by developing innovative technologies and accelerating their translation into commercial products.
These startup founders envision the positive near-term impact their scientific work can have in the world and took the risky steps of forming companies determined to make that vision a reality. In doing so, Wyss Lumineers also lead by example by lighting the way for other scientists to pursue an entrepreneurial path.
Our class of 2022 Wyss Lumineers represent six new startups based on Wyss-developed technologies and cover a breadth of fields and applications, including new approaches to therapeutic discovery and delivery, sustainable food production, and diagnostics for neurological disorders.
Meet the Wyss Lumineers Class of 2022 and their startup companies
Daniele Foresti – AcousticaBio
Faculty advisor: Jennifer Lewis, Sc.D.
- AcousticaBio is using its proprietary fluid processing technology to transform antibody infusions from an in-hospital IV treatment to a painless subcutaneous injection that can be administered anywhere, which could improve the clinical care of millions of patients.
Ciaran Dunn, Shannon Nangle, Marika Ziesack – Circe Bioscience
Faculty advisor: Pam Silver, Ph.D.
- Circe Bioscience is decarbonizing food production by manufacturing food-grade fats inside proprietary microbes through a fermentation process that does not produce but rather uses carbon dioxide, with the goal of making food people want to eat in a massively scalable way without harming the planet.
Jack Jordanides, Jocelyn Kishi, Emma West – Digital Biology
Faculty advisor: Peng Yin, Ph.D.
- Digital Biology is building DNA nanotechnology tools that allow cells in tissue samples to be imaged, then sequenced, and then imaged again.
Daniel Ahlstedt, Jonathan Rittichier, Daniel Wiegand – EnPlusOne Biosciences
Faculty advisor: George Church, Ph.D.
- EnPlusOne is harnessing the power and flexibility of enzymes to deliver RNA-based products to the world with greater efficiency and a lower carbon footprint than existing synthesis methods.
Parastoo Khoshakhlagh, Alex Ng – GC Therapeutics
Faculty advisor: George Church, Ph.D.
- GC Therapeutics uses synthetic biology to program stem cells into any cell type with best-in-class efficiency, speed, and scalability. Their technology dictates cells’ fates in a single step and has been validated for many applications.
Nolan Durr, Sanjay Sharma Timilsina – StataDX
Faculty advisor: Don Ingber, M.D., Ph.D.
- StataDX is a medical diagnostics company building a near-patient diagnostic platform to provide a cost-effective solution to support biomarker-guided therapeutic strategies for patients suffering from chronic conditions including Alzheimer’s, Multiple Sclerosis, ALS, and stroke.
1/6 
2/6 
3/6 
4/6 
5/6 
6/6